Taken together, these results demonstrated that inhibition of AKT enhanced the response of tumor cells to PARP inhibitor in ovarian cancer cell lines with high PARP1 protein expression level, corroborating the effect observed in PDX model study. The gene discussed is AKT1; the disease is ovarian cancer.